Issue 58, 2013

Human lysozyme inhibits the in vitro aggregation of Aβ peptides, which in vivo are associated with Alzheimer's disease

Abstract

Alzheimer's disease is a neurodegenerative disorder characterized by accumulation of Aβ peptide aggregates in the brain. Using ThT fluorescence assays, AFM imaging, NMR and CD spectroscopy, and MD modeling we show that lysozyme – a hydrolytic enzyme abundant in human secretions – completely inhibits the aggregation of Aβ peptides at equimolar lysozyme : Aβ peptide ratios.

Graphical abstract: Human lysozyme inhibits the in vitro aggregation of Aβ peptides, which in vivo are associated with Alzheimer's disease

Supplementary files

Article information

Article type
Communication
Submitted
30 Mar 2013
Accepted
29 May 2013
First published
29 May 2013

Chem. Commun., 2013,49, 6507-6509

Human lysozyme inhibits the in vitro aggregation of Aβ peptides, which in vivo are associated with Alzheimer's disease

J. Luo, S. K. T. S. Wärmländer, A. Gräslund and J. P. Abrahams, Chem. Commun., 2013, 49, 6507 DOI: 10.1039/C3CC42325E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements